Fibrosis: Oncodesign and TiumBio sign collaboration agreement for R&D of drug candidates
Under this agreement, Oncodesign will be responsible for identification, chemical synthesis and optimization of Nanocyclix® drug candidates and their early-stage analysis, while TiumBio will be responsible for the advanced evaluation of fibrotic efficacy of the drug candidates. This initial phase of the collaboration will be funded by TiumBio.
Probes of interest in oncology, immunology, central nervous system diseases and rare diseases
Our chemical-based drug discovery approach has generated a set of potent, selective probes with promising drug-like properties that have not yet been developed. Many of these compounds are active at the sub-nanomolar level and demonstrate exceptional initial selectivity on kinases of major interest.
Oncodesign is committed to promoting partnership opportunities in the early stages of drug discovery. We are looking for partners with complementary skills to develop the therapeutic potential of these small cyclic molecules more quickly.